<DOC>
	<DOC>NCT00822354</DOC>
	<brief_summary>The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.</brief_summary>
	<brief_title>Tadalafil for the Treatment of Raynaud's</brief_title>
	<detailed_description>The primary goal of our study is to decrease the frequency, duration and severity of vasospastic attacks in patients with secondary Raynaud's. The secondary goal is to document increased blood flow and lessened capillary dysfunction in these patients. Both of these goals are to be achieved using a course of treatment with Tadalafil.We anticipate a decrease in the frequency, duration and severity of Raynaud's attacks. Improved digital blood flow and digital blood pressures, and a decrease in digital capillary dysfunction.</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>active Raynaud's Phenomenon stable disease and medication requirements over the previous 2 months subjects willing and able to participate in study assessments ability to understand and sign informed consent ages 18 to 65, both sexes a diagnosis of diffuse or limited cutaneous sclerosis, MCTD using the American College Rheumatology criteria uncontrolled HTN, DM, unstable disease, angina or using oral nitrates smoking, active alcoholism, drug abuse within 5 years abnormal renal function ulnar arterial occlusive disease as shown by a positive Allen Test Pregnant or breast feeding or considering preg. in next 4 months past or present major psych. illness allergy or sensitivity to tadalafil subject unable to understand protocol or give informed consent part. in another study trial within 30 days taking sildenafil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Secondary Raynaud's Phenomenon</keyword>
</DOC>